SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

NEW YORK, April 28, 2024

The investigation concerns whether Supernus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]  

On April 8, 2024, Supernus issued a press release announcing that "[t]he FDA has issued a Complete Response Letter (CRL) in response to the Company's New Drug Application (NDA) for SPN-830", the Company's investigational apomorphine infusion device for the continuous treatment of motor fluctuations ("off" episodes) in Parkinson's disease.  The press release stated that "[t]he CRL indicates that the review cycle for the application is complete, but that the application is not ready for approval in its present form."  Specifically, "[t]he CRL mentions two areas that require additional review by the FDA or additional information to be provided to the FDA", respectively relating to product quality and the master file for the infusion device. 

On this news, Supernus's stock price fell $2.12 per share, or 6.32%, to close at $31.43 per share on April 8, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.